Characterization of Laboratory Working Standard for Quality Control of Immunometric and Radiometric Estrogen Receptor Assays. Clinical Evaluation on Breast Cancer Biopsies
Restricted accessResearch articleFirst published online December, 1989
Characterization of Laboratory Working Standard for Quality Control of Immunometric and Radiometric Estrogen Receptor Assays. Clinical Evaluation on Breast Cancer Biopsies
The objective of the study was to characterize a low-cost and reliable working standard material for quality control of estrogen receptor (ER) determination with dextran-coated charcoal (DCC) and enzyme immunoassay (EIA) methods. Human fibromatous uterine lyophilized cytosol demonstrated good characteristics of stability and applicability for this purpose. Eleven laboratories participated in the intralaboratory and interlaboratory quality control study, and they achieved slightly higher coefficients of variation for ER-EIA (interlaboratory, 37.7 %; intralaboratory, 22.9 %) than for ER-DCC (Interlaboratory, 24.2 %; intralaboratory, 15.7 %). There was an excellent correlation between ER results with ER-EIA and ER-DCC for 268 breast cancer biopsies. Quality assurance for ER assays using DCC techniques and immunometric methods with monoclonal antibodies (ER-EIA) can be set up with this available material of human origin to satisfy the characteristics of both techniques and the species specificity of monoclonal antibodies.
Get full access to this article
View all access options for this article.
References
1.
BoccardoF., BruzziP., CapelliniM., IsolaG., NenciI., PiffanelliA., RubagottiA., SantiL., ScanniA., SismondiP.: Tamoxifen (TMX) vs chemotherapy (CT) vs chemotherapy plus tamoxifen (CTT) in patients with ER positive stage II breast cancer. An interim analysis of a multicentric Italian trial. Breast Cancer Res.Treat.,10: 85, 1987.
2.
BojarH.: Quality control requirements in estrogen receptor determination.Cane. Res. (suppl.),46: 4249–4250, 1986.
3.
Adjuvant Chemotherapy for Breast Cancer Consensus Conference:JAMA, 254: 3461–3463, 1985.
4.
CharpinC., MartinP.M., De VictorB., LavautM.N., HabibM.C., AndracL., TogaM.: Multiparametric study (SAMBA 200) of estrogen receptor immunocytochemical assay in 400 human breast carcinomas: Analysis of estrogen receptor distribution heterogeneity in tissues and correlations with dextran-coated charcoal assays and morphological data.Cancer Res.,48: 1578–1586, 1988.
5.
CofferA.I., LewisK.M., BrockasA.J., KingR.J.B.: Monoclonal antibodies against a component related to soluble estradiol receptor.Cancer Res.,45: 3686–3693, 1985.
6.
Di FronzoG., MiodiniP., BrivioM., CappellettiV., Cora-diniD., GranataG., RonchiE.: Comparison of immunochemical and radioligand binding assay for estrogen receptors in human breast tumors.Cane. Res.,46: 4278–4281, 1986.
7.
EORTC Breast Cancer Cooperative Group:Standards for the assessment of estrogen receptors in human breast cancer.Eur. J. Cancer,9: 379–381, 1973.
8.
EORTC Breast Cancer Cooperative Group:Revision of the standards for the assessment of hormone receptors in human breast cancer.Eur. J. Cancer,16: 1513–1515, 1980; Cancer Res., 45: 3686-3693, 1980.
9.
FisherB., RedmondC., BrownA., WickerhamD.L., WolmarkN., AllegraJ., EsherG., LippmanM., SavlovE., WittliffJ., FisherE.R.: Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.J. Clin. Oncol.,1: 227–241, 1983.
10.
GoussardJ., LechevrelC., MartinP., RussellG.: Comparison of monoclonal antibodies and tritiated ligands for estrogen receptor assays in 241 breast cancer cytosols.Cane. Res.,46: 4282–4287s, 1986.
11.
GreeneG.L., ClossL.E., FlemingH., De SombreE.R., JensenE.V.: Antibodies to estrogen receptor: immunochemical similarity of estrophilin from various mammalian species.Proc. Natl. Acad. Sci. USA,74: 3681–3685, 1977.
12.
GreeneG.L., FitchF.W., JensenE.V.: Monoclonal antibodies to estrophilin: probes for the study of estrogen receptors.Proc. Natl. Acad. Sci. USA,77: 157–161, 1980.
13.
GreenG.L., JensenE.V.: Monoclonal antibodies as probes for estrogen receptor detection and characterization.J. Steroid Biochem.,16: 353–359, 1982.
14.
JensenE.V., JacobsonH.I.: Basic guides to the mechanism of estrogen receptor action.Recent. Prog. Horm. Res.,18: 387–414, 1962.
15.
JordanV., JacobsonH.I., KeenanE.J.: Determination of estrogen receptor in breast cancer using monoclonal antibody technology: results of a multicenter study in the United States.Cancer Res.,46: 4237–4240, 1986.
16.
KingJ.B., CofferA.I., GilbertJ., LewisK., NashR., MillisR., RajuS., TaylorR.W.: Histochemical studies with a monoclonal antibody raised against a partially purified soluble estradiol receptor preparation from human myometrium.Cancer Res.,45: 5728–5733, 1985.
17.
KoendersA., ThorpeS.M.: Standardization of steroid receptor assays in human breast cancer. IV. Long-term within and between-laboratory variation of estrogen and progesterone receptor assays.Eur. J. Cancer Clin. Oncol.,22: 945–952, 1986.
18.
LeclercqG., BojrH., GoussardJ., NicholsonR.I., PichonM., PiffanelliA., PousetteA., ThorpeS., LonsdorferM.: Abbott monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer: A European multicenter study.Cancer Res.,46: 4233–4240, 1986.
19.
MagdelenatH., MerleS., ZajdelaA.: Enzyme immunoassay of receptors in fine needle aspirates of breast tumors.Cancer Res.,46: 4265–4267, 1986.
20.
MarchettiE., QuerzoliP., MoncharmontB., ParikhI., BagniA., MarzolaA., FabrisG., NenciI.: Immunocytochemical demonstration of estrogen receptors by monoclonal antibodies in human breast cancer: correlations with estrogen receptor assay by dextran-coated charcoal method.Cancer Res.,47: 2508–2513, 1987.
21.
NicholsonR.I., ColinP., FrancisA.B., KeshraR., FinlayP., WilliamsM., ElstonC.W., BlarneyR.W., GriffithsK.: Evaluation of an enzyme immunoassay for estrogen receptors in human breast cancers.Cancer Res.,46: 4299–4302, 1986.
22.
PiffanelliA., PelizzolaD., De BortoliM., AgrimontiF., FrairiaR., GiovanniniG., FumeroS.: Quality assurance for steroid receptor assay in human breast cancer: six year experience of the Italian Committee.Tumori,71: 589–596, 1985.
23.
RiccobonA., ZoliW., CapucciA., VolpiA., VasiniM., Bo-naguriC., FlaminiE., RavaioliA., AmadoriD.: Radioligand-labeled binding assay and immunochemical assay for estrogen receptor in 115 human breast cancers.Tumori,74: 167–170, 1988.
24.
ScatchardG.: The attraction of proteins for small molecules and ions.Ann. N.Y. Acad. Sci.,51: 660–672, 1949.
25.
ThorpeS.M.: Quality control of estrogen and progesterone receptor analyses in Denmark.Recent Results Cancer Res.,91: 91–93, 1984.
26.
ThorpeS.M., KoendersA.: Standardization of steroid receptor assay in human breast cancer. III. Selection of reference material for intra and interlaboratory quality control.Eur. J. Cancer Clin. Oncol.,22: 939–944, 1986.
27.
ThorpeS.M., LykkesfeldtA.E., VinterbyA., LonsdorferM.: Quantitative immunological detection of estrogen receptors in nuclear pellets from human breast cancer biopsies.Cancer Res.,46: 4251–4255, 1986.
28.
ToftD., GorskiJ.: A receptor molecule for estrogen: isolation from the rat uterus and preliminary characterization.Proc. Natl. Acad. Sci. USA,55: 1574–1581, 1966.
29.
UrianoG.A., GravattC.C.: The role of the reference materials and reference methods in chemical analysis.Anal. Chem.,6: 361–411, 1977.
30.
WittliffJ.L., WiehleS.A., EckmanJ.B., SmalleyR.V., Bar-tolucciA.A., DurantJ.R.: A quality assurance program for steroid receptor analyses used by the Southeastern Cancer Study Group. In: «Estrogen Receptor Assay in Breast Cancer », Sarfaty and Nash, pp. 105–125, Keightley Masson, 1981.
31.
ZavaD.T., Von BallmoosA.W., GoldhirschA., RoosW., TakahashiA., EppenbergerU., ArrenbrechtS., MartzG., LosaG., GomezF., GuelpaC.: A quality control study to assess the interlaboratory variability of routine estrogen and progesterone receptor assay.Eur. J. Cancer Clin. Oncol.,18: 713–721, 1982.
32.
ZellW.J., SevierE.D.: Protein determination in tumor cytosol by Coomassie brilliant blue G-250 dye-binding.Clin. Chem.,25: 1131, 1979.
